VANCOUVER, British Columbia, April 21, 2026 (GLOBE NEWSWIRE) — LaFleur Minerals Inc. (CSE: LFLR, OTCQB: LFLRF, FSE: 3WK0) (“LaFleur Minerals” or the “Company”) is pleased to report the results from its drilling to date at the Swanson Gold Project, highlighting new gold discovery zones with the presence of broad, continuous zones of gold mineralization that extend well below the limits of the current resource model, expanding and confirming the potential for a large-scale gold system. Four (4) diamond drill holes, completed between vertical depths of approximately 300 and 450 metres and spaced over a 120-metre strike length, were specifically designed to test the down-dip continuity of the Swanson Gold Deposit. These results confirm that the new gold discovery mineralized system remains robust at depth and continues to expand beyond...

Results from Part 1 of the Phase 1b MUIR trial to be presented at annual meeting in June SAN DIEGO, April 21, 2026 (GLOBE NEWSWIRE) — Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that the American Society of Clinical Oncology (ASCO) has accepted an abstract for presentation at the 2026 ASCO Annual Meeting, which will be held June 1-5, 2026, in Chicago, IL. “We are pleased that data from Part 1 of the MUIR trial focusing on azenosertib in combination with paclitaxel in platinum-resistant ovarian cancer (PROC) have been accepted for presentation at ASCO,” said Julie Eastland, Chief Executive Officer of Zentalis. “Paclitaxel...

May 5 at 4:30 p.m. EDTSkyworks Sets Date for Second Quarter Fiscal 2026 Earnings Release and Conference CallSkyworks Sets Date for Second Quarter Fiscal 2026 Earnings Release and Conference Call May 5 at 4:30 p.m. EDTIRVINE, Calif., April 21, 2026 (GLOBE NEWSWIRE) — Skyworks Solutions, Inc. (Nasdaq: SWKS), an innovator of high-performance analog and mixed-signal semiconductors connecting people, places and things, will host a conference call with analysts to discuss its second quarter fiscal 2026 results and business outlook on May 5, 2026, at 4:30 p.m. EDT.  After the close of the market on May 5, and prior to the conference call, Skyworks will issue a copy of the earnings press release via GlobeNewswire. The press release may also be viewed on Skyworks’ website at www.skyworksinc.com/investors. To listen to the conference...

Houston, Texas and Tuebingen, Germany, April 21, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, today announced all submitted abstracts have been selected for oral presentations at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held from May 29-June 2, 2026, in Chicago, Illinois, USA. The four oral presentations will include:Phase 1b clinical data on anzu-cel, the Company’s lead PRAME cell therapy, in advanced cutaneous and uveal melanoma with a focus on characterizing response dynamics Updated Phase 1a dose-escalation and Phase 1b dose-expansion data for the second-generation (GEN2) PRAME cell therapy candidate, IMA203CD8, in gynecologic cancers at clinically...

Poster to be presented at the American Society for Clinical Oncology on Monday, June 1, 2026 BELTSVILLE, Md., April 21, 2026 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer and Simcere Zaiming Pharmaceutical Co., Ltd., (Simcere) an oncology-focused biopharmaceutical company and a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096), today announced a poster will be presented at ASCO 2026 highlighting Phase 1 data for SIM0505 in the treatment of solid tumors. ASCO 2026 is being held May 29 – June 2 in Chicago, Illinois. SIM0505 is an investigational antibody drug conjugate (ADC) targeting Cadherin-6 (CDH6) with a proprietary topoisomerase 1 inhibitor (TOPOi) payload. “We are...

DOYLESTOWN, Pa., April 21, 2026 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today announced the acceptance of an abstract “Early results from the first-in-human phase 1 study of WEE1 inhibitor APR-1051 in patients with advanced solid tumors (ACESOT-1051)” at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, to take place May 29 – June 2, 2026, in Chicago, IL.  Presentation Details:Title: Early results from the first-in-human phase 1 study of WEE1 inhibitor APR-1051 in patients with advanced solid tumors (ACESOT-1051)Presenting author: Shiraj Sen, MD. PhD., NEXT Oncology Dallas, TXSession: Poster...

NANJING, China, April 21, 2026 (GLOBE NEWSWIRE) — Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that the first patient has been successfully dosed in a phase Ⅱ clinical study evaluating Opamtistomig (LBL-024), the company’s core investigational PD-L1/4-1BB bispecific antibody, for the first-line treatment of locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma. Early symptoms of gastric cancer are often subtle and easily overlooked, leading to most patients being diagnosed at an advanced stage and facing a generally poor prognosis. PD-1 antibody combined with chemotherapy is recommended as the first-line treatment for advanced disease, with median progression-free survival (PFS) at only 7 months and median overall survival (OS) ranging from 13...